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ABSTRACT (200 words) 31 
Fetal growth restriction (FGR) is a complication of pregnancy that reduces birth weight, 32 
markedly increases infant mortality and morbidity and is associated with later-life cardiometabolic 33 
disease.  No specific treatment is available for FGR. Placentas of human FGR infants have low abundance 34 
of sodium-coupled neutral amino acid transporter 2 (Slc38a2/SNAT2), which supplies the fetus with amino 35 
acids required for growth. We determined the mechanistic role of placental Slc38a2/SNAT2 deficiency in 36 
the development of restricted fetal growth, hypothesizing that placenta-specific Slc38a2 knockdown 37 
causes fetal growth restriction in mice. Using lentiviral transduction of blastocysts with a small hairpin 38 
RNA, we achieved 59% knockdown of placental Slc38a2, without altering fetal Slc38a2 expression. 39 
Placenta-specific Slc38a2 knockdown reduced near-term fetal and placental weight, fetal viability, 40 
trophoblast plasma membrane SNAT2 protein abundance, and both absolute and weight-specific 41 
placental uptake of the amino acid transport System A tracer, 14C-methylaminoisobutyric acid. We also 42 
measured human placental SLC38A2 gene expression in a well-defined term clinical cohort and found that 43 
SLC38A2 expression was decreased in late-onset, but not early-onset FGR, compared to appropriate for 44 
gestational age control placentas. The results demonstrate that low placental Slc38a2/SNAT2 causes fetal 45 
growth restriction and could be a target for clinical therapies for late-onset FGR.  46 
KEYWORDS: Maternal-fetal exchange, fetal growth restriction, syncytiotrophoblast, amino acid transport 47 
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CLINICAL PERSPECTIVES 49 
 Fetal growth restriction is an obstetric disease that severely compromises perinatal survival and 50 
long-term health of the infant. The biological mechanisms underlying fetal growth restriction are 51 
unknown, preventing us from developing treatments. 52 
 We show that experimental knockdown of Slc38a2 in the mouse placenta reduces fetal weight at 53 
the end of gestation, demonstrating a cause-and-effect relationship between low placental 54 
Slc38a2/SNAT2 expression and fetal growth restriction in vivo.  We also show that human 55 
placental Slc38a2 expression is specifically reduced in late-onset fetal growth restriction. 56 
 Our findings support the concept that placental SNAT2 deficiency underpins human FGR and 57 
suggest that interventions that augment placental amino acid transport could improve fetal 58 
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Fetal growth restriction (FGR) is a pregnancy complication characterized by abnormal placental function 61 
and low birth weight (1). FGR severely compromises neonatal survival (2) and infant lifelong health (3, 4). 62 
There is currently no cure and the underlying mechanisms remain poorly understood. FGR is associated 63 
with reduced placental amino acid transport capacity and reduced umbilical concentrations of amino acids 64 
(5-8), which provide substrate for fetal tissue accretion (9-11) and stimulate the secretion of growth 65 
hormones in utero (12, 13). In particular, System A amino acid transport capacity is low in the maternal-66 
facing syncytiotrophoblast microvillous plasma membrane of human FGR placentas (14-16), suggesting 67 
that impaired placental System A transport contributes to the deficit in fetal nutrient supply. 68 
System A transporters mediate sodium-dependent, active accumulation of small neutral amino acids from 69 
the maternal blood into the syncytiotrophoblast epithelium (reviewed in (17)).  Active transport of amino 70 
acids into the placenta is critical for their transepithelial transfer to the fetus, where amino acid 71 
concentrations are higher than in the mother (6, 7, 18). Amino acids accumulated by System A also drive 72 
the placental uptake of large, branched-chain amino acids, including essential amino acids like leucine, via 73 
microvillous membrane System L exchangers (19-21). System A activity is attributed to three Sodium-74 
Coupled Neutral Amino Acid Transporter (SNAT) protein isoforms: SNAT1, SNAT2 and SNAT4, which have 75 
all been localized to the human placental microvillous membrane (22-25). Human FGR has been linked to 76 
reduced placental SNAT2 abundance (22, 26).  77 
Experimental manipulations that specifically reduce plasma membrane SNAT2 abundance in primary 78 
human trophoblast cells inhibit System A activity in vitro (27), and impaired placental System A activity 79 
temporally precedes FGR in undernourished rats and baboons (28-30), suggesting that SNAT2 deficiency 80 
mechanistically contributes to the development of FGR. In pregnant rodents, systemic pharmacological 81 
inhibition of System A activity, using a non-metabolizable, competitive synthetic substrate, reduces fetal 82 
weight (31). Moreover, in mouse embryos, placental and fetal size are both diminished by global deletion 83 
of either Slc38a1, Slc38a2 or Slc38a4, which encode SNAT1, SNAT2 and SNAT4, respectively (32). Global 84 
deletion of Slc38a2 also reduces perinatal survival in mouse pups (33). Other genetic, environmental and 85 
hormonal manipulations that reduce intrauterine growth in mice frequently tend to decrease placental 86 
SNAT2 abundance and System A activity, measured by unidirectional maternal-fetal clearance of the 87 
tracer methylaminoisobutyric acid (MeAIB) (34-38). However, to date, there has been no demonstration 88 
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FGR is also strongly associated with lower fetal insulin, glucose-stimulated insulin secretion (GSIS), islet 91 
size, and β-cell number (39). Decreased amino acid transfer from the placenta to the fetus is concomitant 92 
with defective fetal pancreatic islet structure and function in FGR sheep fetuses whilst chronic fetal amino 93 
acid infusion restores fetal GSIS, pancreatic vascularity, islet size and β-cell mass (40, 41). However, there 94 
is no definitive in vivo genetic evidence of placental amino acid transporter involvement in regulating fetal 95 
islet function.  96 
Clinically, FGR is increasingly recognized as either early- or late-onset disease. By definition, early- and 97 
late-onset FGR are diagnosed before and after 32 weeks of gestation, respectively, and have distinct 98 
phenotypes (42-44). Early-onset FGR is strongly associated with pre-eclampsia, maternal vascular 99 
malperfusion of the placenta, abnormal umbilical artery Doppler measurements, fetal hypoxia, preterm 100 
delivery and fetal demise (44-46). Contrastingly, late-onset FGR is less commonly associated with pre-101 
eclampsia, vascular abnormalities or fetal mortality but affects a larger proportion of pregnancies, is a 102 
common cause of stillbirth and carries a similar burden of poor long term neurodevelopmental and 103 
cardiometabolic outcomes in the neonate (44). The respective contribution of placental amino acid 104 
transport to early- and late-onset FGR has not been investigated, and the aetiology of late-onset FGR is 105 
particularly unclear. 106 
We hypothesized that placenta-specific Slc38a2 knockdown causes fetal growth restriction and impairs 107 
fetal islet GSIS in mice. We used a lentiviral vector to deliver a small hairpin (sh) RNA gene silencing 108 
construct to the blastocyst trophectoderm in early gestation (47-51) and subsequently determined 109 
placental and fetal weight, in vivo placental amino acid transport capacity and placental amino acid 110 
transporter abundance near term. We also measured glucose-stimulated insulin secretion in isolated fetal 111 
islets from fetuses with placenta-specific Slc38a2 knockdown.  Finally, we quantified human placental 112 
SLC38A2 gene expression in placentas from pregnancies with early-onset or late-onset FGR, compared to 113 
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MATERIALS AND METHODS 115 
Lentiviral vectors 116 
The small hairpin RNA (shRNA) gene silencing plasmid, targeting the mouse Slc38a2 mRNA (Slc38a2KD), 117 
was based upon the pLKO.1 vector (52) and obtained from a commercial vendor (VectorBuilder Inc., 118 
Chicago, IL, USA). Targeting sequence (TCACGGTCCCAGTAGTTATTT), hairpin loop (CTCGAG) and guide 119 
sequence (AAATAACTACTGGGACCGTGA) were inserted in series into the plasmid backbone, downstream 120 
of the human U6 small nuclear 1 promoter. The plasmid backbone also contained an enhanced green 121 
fluorescent protein (EGFP) open reading frame expressed from the human phosphoglycerate kinase 1 122 
promoter and an ampicillin resistance gene. A control plasmid (SCR), with scrambled targeting sequence 123 
(CCTAAGGTTAAGTCGCCCTCG), was constructed similarly. E. coli glycerol stocks of both plasmids were 124 
amplified in overnight cultures of LB broth with 100 μg ml-1 ampicillin then DNA was isolated using a 125 
commercially available kit (Plasmid Maxi kit, Qiagen).  Targeting and control plasmids were then packaged 126 
into vesicular stomatitis virus G pseudotyped lentiviral particles by co-transfecting 293FT cells with the 127 
isolated DNA (440 ng ml-1, with Qiagen Polyfect 1% v/v in culture medium), together with packaging (330 128 
ng ml-1 pCMV delta 8.9) and envelope plasmids (140ng ml-1 pCMV-VSV-G (53)), obtained from the 129 
Functional Genomics Shared Resource at the University of Colorado Cancer Centre. Human 293FT (female 130 
embryonic kidney epithelial) cells were purchased from Thermo Fisher Scientific and cultured at 37°C in 131 
complete medium (Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 0.1mM non-132 
essential amino acids, 6mM glutamine, 1mM sodium pyruvate and 1% pen-strep). Lentiviral particles were 133 
isolated from the filtered culture medium 72 hr after transfection by ultracentrifugation over 20% sucrose 134 
(22 000 RPM, 2 hr) then resuspended in PBS. The functional titer of each batch of lentivirus, in 135 
transforming units per ml, was quantified by transducing 293FT cells with serial dilutions of the viral 136 
suspension then determining the percentage of EGFP fluorescent cells using flow cytometry. 137 
Lentiviral transduction of mouse blastocysts and surgical embryo transfer 138 
All animal procedures were carried out at the University of Colorado with approval from the Institutional 139 
Animal Care and Use Committee (Protocol #344). B6D2F1 mice were purchased from Charles River 140 
Laboratories (Wilmington, MA, USA) and CD-1 mice were purchased from Jackson Laboratories (Bar 141 
Harbor, ME, USA).  All animals were maintained under standard 14 hr: 10 hr light: dark conditions with ad 142 
libitum access to food and water. Female B6D2F1 mice (n=140), aged <4 weeks, were injected with 143 
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gonadotrophin (5 I.U., i.p., Sigma-Aldrich, St Louis, MO, USA) to induce superovulation, then mated 145 
overnight with stud B6D2F1 males. Successfully mated females were identified by the presence of a 146 
copulatory plug the following morning, which was designated embryonic day (E) 0.5 (term ≈ E19.5). On 147 
E3.5, pregnant females were euthanized by CO2 asphyxiation and cervical dislocation, their uteri excised 148 
and each horn flushed with 5 ml of pre-warmed M2 medium (M7167, Sigma-Aldrich, St Louis, MO, USA). 149 
Flushed blastocysts were denuded of the zona pellucida by serially incubating in three drops of acidic 150 
Tyrodes solution (~10s each) then washed and incubated in embryo culture medium (EmbryoMax 151 
Advanced KSOM Embryo medium, MR-101-D, Millipore). The trophectoderm was then transduced with 152 
either Slc38a2KD or SCR by incubating batches of 5-10 blastocysts with either 5 x 105 or 5 x 106 153 
transforming units of lentivirus in a total volume of 20μl, for 4 hours. Blastocysts were subsequently 154 
washed in 12 drops of embryo culture medium and surgically transferred to pseudopregnant female CD-155 
1 recipients.   All in vitro manipulations were performed at 37⁰C and under low light conditions. 156 
Female CD-1 embryo recipient mice (n=74) were mated overnight with vasectomized B6D2F1 males, to 157 
induce pseudopregnancy, and underwent surgical embryo transfer 2.5 days post-copulation. Recipients 158 
were given pre-operative analgesia (meloxicam, 1 mg/kg, i.p.) then anaesthetized with isofluorane (2%, 159 
inhaled). With the animal in sternal recumbency and under aseptic conditions, a 0.5 cm incision was made 160 
in the skin of the flank overlying the right ovary, 1cm caudal to the rib cage. Ovary, oviduct and distal 161 
uterine horn were exteriorized through the body wall and a 26ga needle used to puncture the uterus 162 
below the oviductal junction. Lentivirus transduced blastocysts (7-12) were then gently inserted into the 163 
uterine horn in a minimal volume of culture medium. The uterus and oviducts were then returned to the 164 
body cavity, the body wall closed with a single absorbable suture (5.0 vicryl) and the skin closed with a 165 
9mm wound clip. The procedure was then repeated for the left ovary, with Slc38a2KD and SCR transduced 166 
blastocysts transferred to contralateral horns of the same uterus and randomized to left and right in each 167 
recipient. Post-operatively, recipient females were recovered from anesthesia on a heated mat and 168 
housed in pairs. 169 
In vivo transplacental amino acid clearance and tissue collection 170 
Fetal and placental phenotype were assessed on E17.5 (n=16) or E18.5 (n=58). System A and System L-171 
mediated placental amino acid transport capacity were measured in a subset of  E18.5 pregnant recipient 172 
females (n=16), by measuring maternal-placental and maternal-fetal clearance of non-metabolizable, 173 
radiolabeled 14C-methylaminoisobutryic acid (14C-MeAIB) and 3H-leucine, respectively. Dams were 174 
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The lateral tail vein was cannulated and flushed with heparinized saline using a 28ga needle attached to 176 
a 0.5ml insulin syringe, via polyethylene (PE20) tubing (0.38mm I.D., ~12cm length, B.D. Intramedic 177 
427405, Becton Dickinson, NJ, USA). A combined bolus of 14C-MeAIB (50μCi/kg, specific activity 178 
58.7mCi/mmol) and 3H-leucine (250μCi/kg, specific activity 60000mCi/mmol) was delivered to the tail 179 
vein, with flushing. At exactly 1.5, 3 or 4.5 minutes later, the dam was euthanized with sodium 180 
pentobarbital (390mg/ml, 100μl, i.v.) and a cardiac blood sample rapidly collected into a heparinized 181 
syringe. The blood was then centrifuged (12000 rpm, 4 min, 4°C) and the supernatant plasma separated 182 
and frozen. The uterus was exposed via laparotomy and the number of viable fetuses and non-viable 183 
resorptions counted in each horn. Fetuses and placentas were dissected from the uterus and membranes, 184 
blotted briefly and weighed. Individual fetuses and placentas were then solubilized in Biosol (1ml for 185 
placenta, 3ml for fetus, National Diagnostics) at 55°C, overnight. Aliquots of maternal plasma and fetal 186 
digestate were subsequently cleared with hydrogen peroxide and their radioactivity determined by liquid 187 
scintillation counting. Initial experiments determined that the ratio of fetal to maternal plasma 188 
radioactivity per unit volume increased linearly with respect to time until at least 3 min after injection of 189 
both tracers, indicating unidirectional maternal-fetal flux in this time period (Fig S5). Therefore, a 190 
clearance curve of maternal plasma radioactivity per ml versus time from tracer injection was constructed 191 
from these experiments and used to calculate net maternal-placental and maternal-fetal clearance of 14C-192 
MeAIB and 3H-leucine for all pregnant dams euthanized at 1.5 min or 3 min after tracer injection, as 193 
described (54). The remaining recipient dams that did not undergo tracer measurements (n=58) were 194 
euthanized by CO2 asphyxiation and cervical dislocation and fetuses and placentas counted, weighed and 195 
snap frozen in liquid N2. In a subset of litters (n=6), fetal liver, heart, brain and skeletal muscle were 196 
dissected and pooled for SCR and Slc38a2KD fetuses, within each litter. In a different subset of litters 197 
(n=3), placentas were dissected into their constituent labyrinthine and junctional zones and frozen for 198 
gene expression analysis. In all cases, embryo implantation rate was determined as the sum of viable and 199 
resorbed conceptuses divided by number of embryos transferred, whilst viability rate was determined as 200 
the number of viable conceptuses divided by number of embryos transferred.  201 
Gene expression analysis 202 
RNA was extracted from frozen placentas and fetal tissues and reverse transcribed using commercially 203 
available kits (RNeasy Plus Mini kit, Qiagen and High-Capacity cDNA RT kit, Invitrogen). The expression of 204 
Slc38a1, Slc38a2 and Slc38a4 was determined by SYBR green qRT-PCR using the relative standard curve 205 
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Trophoblast plasma membrane isolation 207 
For analyses of transporter and signaling protein abundance, pools of SCR and Slc38a2KD placentas were 208 
created from multiple litters. Pools contained between 3 and 11 individual placentas and were matched 209 
such that each Slc38a2KD pool (n=10) comprised placentas from the same litters as the corresponding 210 
SCR pool (n=10). Pooled frozen tissue was homogenized in buffer D (250 mM sucrose, 10 mM Hepes-Tris, 211 
and 1 mM EDTA (pH 7.4)) with protease and phosphatase inhibitors. Trophoblast plasma membrane 212 
(TPM) vesicles were isolated from the homogenate using differential ultracentrifugation and Mg2+-213 
precipitation, as previously described (55). Briefly, homogenates were serially centrifuged at 10, 000 g 214 
(10min, 4⁰C) and 125, 000 rpm (30min, 4⁰C) to remove tissue debris and nuclei. The resultant pellet was 215 
resuspended and the TPM precipitated by addition of MgCl2 (12mM) with stirring, on ice. Precipitated 216 
TPM was then isolated by further ultracentrifugation (33 000 rpm, 30min, 4⁰C), resuspended and 217 
vesiculated using a Dounce homogenizer. Homogenate and TPM protein content were determined by 218 
bicinchoninic acid assay and the enrichment of the preparation determined by the ratio of alkaline 219 
phosphatase activity, per unit protein in the TPM compared to crude homogenate. Average TPM 220 
enrichment ratios were similar in SCR (8.9 ± 1.2) and Slc38a2KD (7.7 ± 0.8) pools (P=0.275).  221 
Fetal pancreatic islet isolation and measurement of glucose-stimulated insulin secretion 222 
Fetal islet function was measured in a subset of litters at E18.5 (n=7). Fetuses were dissected, glucose 223 
concentrations in trunk blood measured using a hand-held glucometer and fetal pancreata dissected and 224 
pooled for SCR and Slc38a2KD conceptuses within each litter. Pancreata were digested at 37°C for 10–15 225 
min with Hanks’ balanced salt solution (Life Technologies) containing  2.5% bovine serum albumin (BSA) 226 
(wt/vol; Sigma), 0.35 g/L NaHCO3 (Sigma), and 2 mg/mL Collagenase P (Roche). Digested tissue was then 227 
washed in the cold, supplemented Hanks balanced salt solution without collagenase. Islets were isolated 228 
by histopaque gradient centrifugation and washed. Isolated islets were snap frozen in liquid N2 or cultured 229 
(50/sample) in RPMI medium for 2 hr, preconditioned in Krebs–Ringer bicarbonate buffer for 90 min, and 230 
then incubated for 60 min with either 2.8 or 10.0 mM glucose in the same buffer. Subsequently, the 231 
supernatant was collected and stored at −80°C for later analysis of insulin content by ELISA (Alpco, NH, 232 
USA). 233 
Immunoblotting 234 
SNAT2 abundance in TPM (n=9 paired SCR and Slc38a2KD pools) and Pdx1 (pancreatic and duodenal 235 
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western blot. Equal amounts of protein from each sample pool were resolved on a polyacrylamide gel, 237 
under reducing, denaturing conditions, then transferred to polyvinylidene fluoride membrane, overnight. 238 
Membranes were probed with rabbit polyclonal antibodies raised against SNAT2 (56) or a commercially 239 
available monoclonal Pdx1 antibody (#5679, Cell Signaling Technology) and visualized using an HRP-240 
conjugated secondary antibody and enhanced chemiluminescence reaction, in an automated gel imaging 241 
system. Band intensities were quantified by densitometry and normalized for total protein load, 242 
determined by amido black staining. Amino acid response and mTOR signaling pathway activity in crude 243 
placental homogenates was also determined by western blot for total and phosphorylated forms of eIF2α 244 
(Ser51), S6 (Ser235/236), 4EBP1 (Thr37/46) and Akt (Ser473). 245 
Analysis of human placental SLC38A2 expression in FGR and AGA pregnancies 246 
Placentas were collected from pregnant women who were prospectively recruited at University College 247 
London Hospital, London, UK. All women had their Estimated Date of Delivery (EDD) calculated from their 248 
last menstrual period (LMP) confirmed by ultrasound in the first trimester. Women with pregnancies 249 
affected by early-onset FGR were defined by ultrasound-assessed estimated fetal weight (EFW) <600g and 250 
<3rd centile, between 20 and 26+6 weeks of gestation (46, 57). Women with pregnancies affected by late-251 
onset FGR were defined as having a normal sized fetus at their mid-gestation anomaly scan (EFW ≥10th 252 
centile for gestation) but had an EFW<10th centile diagnosed after 32 weeks, and delivered at term. 253 
Women with early FGR delivered either preterm (<37 weeks of gestation) or at term (≥37 weeks of 254 
gestation). Women with AGA fetuses (10th-95th centile) delivered at term and were recruited as part of a 255 
case-control study (58-60). Exclusion criteria included multiple pregnancy, maternal age <18 years, fetal 256 
structural or chromosomal abnormalities, premature preterm rupture of membranes or maternal 257 
bacterial or viral infection. 258 
At delivery of liveborn infants, placental villous tissue was sampled from two points midway between the 259 
umbilical cord insertion and margin, dissected free of decidua and chorionic plate and snap frozen in liquid 260 
nitrogen, or placed in RNAlater. RNA was subsequently extracted from tissue stored at -80°C, using a 261 
commercially available kit (RNeasy Fibrous Tissue Mini Kit, Qiagen). Following reverse transcription, 262 
placental SLC38A2 expression was quantified using Taqman RT-qPCR, normalized to the geometric mean 263 
of 18S (ribosomal 18S RNA), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), YWHAZ (tyrosin 3-264 
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Results from experimental analyses in mice are mean ± SEM unless indicated otherwise. Categorical data 267 
on implantation and viability rate were analysed by Fisher’s exact test. Discontinuous data on litter size 268 
were analysed by non-parametric Mann-Whitney test. Gene expression, morphometric and placental 269 
transport data were determined for every viable conceptus within each litter then a litter mean value for 270 
SCR and Slc38a2KD conceptuses calculated and used for statistical analysis.  SCR and Slc38a2KD litter 271 
means were compared by two-tailed Student’s t-test, paired within each litter. The linear relationship of 272 
individual fetal weights with placental Slc38a2 expression or amino acid transport was determined by 273 
Pearson’s product-moment correlation. Transporter and signaling protein abundances determined for 274 
matched pools of SCR and Slc38a2KD placentas were also compared by paired Student’s t-test. 275 
Results from human subjects are median (interquartile range) for continuous data, or number (% of group 276 
total) for categorical data. Analyses were based on comparison of subjects within term-delivered AGA, 277 
late-onset FGR and early-onset FGR, and preterm-delivered early-onset FGR study groups.  For categorical 278 
data, proportions of each group total were compared across study groups by chi-squared test. For 279 
continuous data, normality of residuals was assessed by Shapiro-Wilk test then intergroup comparisons 280 
were made by one-way ANOVA with Sidak’s multiple comparisons post-hoc or by Kruskal-Wallis test with 281 
Dunn’s multiple comparison’s post-hoc, as appropriate. Post-hoc comparisons were conducted in a 282 
planned manner, between term AGA, late- and early-onset FGR subjects, then separately between term 283 
and preterm early-onset FGR subjects. Correlation and regression analyses were performed for subjects 284 
delivering at term only. Interdependence of continuous variables was assessed by Pearson’s correlation. 285 
The effect of FGR status on placental SLC38A2 expression, adjusted for potential confounding continuous 286 
and categorical variables, was determined using main effects multiple linear regression, with SLC38A2 as 287 
the dependent variable. In all cases, significance was at P<0.05. Statistical details of experiments can be 288 
found in figure and table legends. 289 
Study approval 290 
Human subjects were recruited with written informed consent and ethical approval from UK National 291 
Health Service Research Ethics Committees (London – Hampstead Research Ethics Committee, REC 292 
reference 15/LO/1488 and Stanmore Research Ethics Committee, REC reference 13/LO/1254). 293 
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Placenta-specific lentiviral transduction of mouse embryos 296 
B6D2F1 mouse blastocysts were transduced with a lentiviral shRNA vector targeting Slc38a2 (Slc38a2KD), 297 
on day (E) 3.5 post-conception, to silence the Slc38a2 mRNA specifically in the trophectoderm cells, which 298 
form the definitive placenta (61) (see Methods). Control blastocysts were transduced with a scrambled, 299 
non-targeting vector (SCR). Both lentiviral vectors expressed a green fluorescent protein (GFP) reporter 300 
driven by the human phosphoglycerate kinase 1 promoter. Irrespective of shRNA construct, blastocysts 301 
transduced with either 5 x 105 or 5 x 106 transforming units of lentivirus, but not with lower viral titers, 302 
expressed GFP immediately after the 4 hr transduction period and 24 hr later (Fig. S1A). When blastocysts 303 
were surgically transferred to pseudopregnant CD-1 recipient female mice, those embryos transduced 304 
with 5 x 106 transforming units produced fewer viable fetuses near term (1%, 2 fetuses/159 embryos 305 
transferred, 10 recipients) and fewer total implantations (8%, 12 implantation sites/159 embryos 306 
transferred) than embryos transduced with 5 x 105 transforming units (27% viability rate, 336 307 
fetuses/1255 embryos and 33% implantation rate, 410 implantation sites/1255 embryos; 64 recipients 308 
P<0.001 Fisher’s exact test, E17.5 and E18.5 combined). Therefore, subsequent analyses of intrauterine 309 
growth used blastocysts incubated with 5 x 105 transforming units of lentivirus. SCR and Slc38a2KD 310 
transduced blastocysts were transferred to contralateral horns of each recipient uterus. Ninety-five 311 
percent of viable conceptuses (329/336) exhibited placenta-specific GFP reporter expression at term (Fig. 312 
S1B) and GFP negative conceptuses (5%, 17/336) were excluded from morphometric analyses. 313 
Placenta-specific Slc38a2 knockdown reduces fetal and placental weight 314 
On E17.5, implantation and viability rate were similar in SCR and Slc83a2KD conceptuses (Table S1).  315 
Slc38a2 expression was 26% lower in Slc38a2KD than SCR placentas (Fig. S2A). Placenta weight (-15%), 316 
but not fetal weight, was lower in Slc38a2KD conceptuses than SCR conceptuses (Fig. S2B, C). However, 317 
there was a trend for fetal weight to be lower by 7% (P=0.059). We therefore sought to determine the 318 
effect of placental Slc38a2 knockdown closer to term, at E18.5, because the mouse fetus grows rapidly 319 
over this period, gaining weight by 2-3-fold between E16.5 and E18.5 (62). 320 
On E18.5, implantation rate was similar in SCR and Slc38a2KD embryos (Table 1). However, a smaller 321 
proportion of the Slc38a2KD embryos gave rise to viable fetuses, resulting in fewer viable Slc38a2KD 322 
conceptuses than SCR conceptuses per uterine horn (Table 1). Only litters of at least 4 viable fetuses in 323 
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number of fetuses per horn in this subset: SCR, 4; Slc38a2KD, 3, P=0.009, n=29 litters). Placental Slc38a2 325 
mRNA expression was 59% lower in Slc38a2KD conceptuses than SCR conceptuses, whereas Slc38a1 and 326 
Slc38a2 expression were similar in the two groups, as expected (Fig. 1A). Similarly, when placentas were 327 
dissected to separate the nutrient-transporting labyrinthine zone from the hormone-producing junctional 328 
zone, Slc38a2KD reduced Slc38a2 mRNA expression in both zones, without altering Slc38a1 or Slc38a2 329 
expression, even though basal expression of all three transporters was higher in the labyrinth than in the 330 
junctional zone (Fig. S3). Slc38a2 mRNA expression in non-placental tissues did not differ between SCR 331 
and Slc38a2KD conceptuses, in either the fetal liver, heart, brain or skeletal muscle (Fig. 1B), consistent 332 
with trophoblast-specific knockdown of the target gene. 333 
Placenta-specific Slc38a2 knockdown reduced fetal weight by 11% compared to SCR controls (Fig. 1C), 334 
consistent with our original hypothesis, and despite fewer Slc38a2KD fetuses per litter. Slc38a2KD also 335 
reduced placental weight by 18% (Fig. 1D). When SCR and Slc38a2KD conceptuses were combined, fetal 336 
weight correlated with placental Slc38a2 expression (Fig. 1E), whereas placental weight did not (R=0.305, 337 
P=0.052, n=41). The frequency distribution of fetal weights in Slc38a2KD conceptuses was left-shifted, 338 
compared to SCR conceptuses (Fig. 1F) such that a greater proportion of Slc38a2KD fetuses (22%) were 339 
below the 10th centile of control fetal weight (854g, P=0.015, Fisher’s exact test), consistent with the FGR 340 
clinical phenotype. 341 
To investigate the mechanism linking placenta-specific Slc38a2 silencing with reduced placental weight, 342 
we also determined the activity of the nutrient-sensing amino acid response and mTOR (mechanistic 343 
target of rapamycin) signaling pathways in SCR and Slc38a2KD placentas, using western blotting. 344 
Slc38a2KD affected neither abundance nor phosphorylation of eIF2α (Ser51), which is responsive to amino 345 
acid deprivation,  or the read-outs of mTOR activity, S6 ribosomal protein (Ser235/236), eukaryotic 346 
translation initiation factor 4E-binding protein (4EBP1, Thr37/46) and protein kinase B (Akt, Ser473) (Fig. S4). 347 
Placenta-specific Slc38a2 knockdown reduces placental System A amino acid transport  348 
Next, we used immunoblotting to determine SNAT2 protein abundance in the isolated trophoblast plasma 349 
membrane of E18.5 SCR and Slc38a2KD placentas, because membrane translocation of the transporter is 350 
required for cellular amino acid accumulation and known to be post-translationally regulated in 351 
trophoblasts (26). Trophoblast plasma membrane SNAT2 was 30% lower in Slc38a2KD than in SCR 352 
placentas, in line with Slc38a2 mRNA expression (Fig. 2A). Placental System A amino acid transport 353 
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uptake) and maternal-fetal clearance (transplacental transport) of non-metabolizable 14C-MeAIB (see 355 
Methods). Slc38a2KD reduced both placental uptake and transplacental transport of 14C-MeAIB, 356 
consistent with an overall reduction in placental System A transport capacity (Fig. 2B, C). Placental uptake 357 
of 14C-MeAIB was also lower in Slc38a2KD than SCR conceptuses when expressed per gram of placental 358 
weight (Fig 2D). However, there was no significant difference between SCR and Slc38a2KD conceptuses 359 
when transplacental 14C-MeAIB transport was expressed per gram of placenta (Fig. 2E), indicating that the 360 
mass-specific System A transport activity of the placenta was maintained, despite its smaller size. Fetal 361 
weight was positively correlated with placental uptake of 14C-MeAIB, when each conceptus within each 362 
litter was considered as an individual (Fig. 2F). We similarly determined maternal-placental and maternal-363 
fetal clearance of 3H-leucine, as read-outs of placental System L exchanger activity. Both placental uptake 364 
and transplacental clearance of 3H-leucine were lower in Slc38a2KD than SCR conceptuses as absolute 365 
values, but not when expressed per gram of placenta (Fig. 3).  366 
Placenta-specific Slc38a2 knockdown decreases fetal islet glucose-stimulated insulin secretion  367 
Glucose-stimulated insulin secretion (GSIS) was measured ex vivo in pancreatic islets isolated from a 368 
subset of Slc38a2KD and SCR fetuses at E18.5. Islet GSIS did not differ between  Slc38a2KD and SCR fetuses 369 
in the presence of 2.8 mM glucose but was significantly lower in Slc38a2KD fetuses than SCR fetuses at 370 
10.0 mM glucose (Fig. 4A, B). Fetal glucose concentrations were similar in the two groups (Fig. 4C). 371 
Placenta-specific Slc38a2 knockdown reduced fetal islet abundance of the transcription factor Pdx1, a 372 
master-regulator of β cell differentiation (Fig. 4D). 373 
Human placental SLC38A2 gene expression is decreased in late- but not early-onset FGR. 374 
Finally, we quantified SLC38A2 expression in human placentas collected at term from AGA, early- and late-375 
onset FGR neonates , with informed consent in a UK hospital setting.  Because early-onset FGR is 376 
frequently associated with preterm delivery, we separately compared SLC38A2 expression in early-onset 377 
FGR placentas delivered at term with those delivered preterm (<37 weeks of gestation). Maternal age and 378 
pre-pregnancy body mass index (BMI) and the proportional distributions of fetal sex and delivery mode 379 
were similar in AGA and FGR groups, irrespective of gestational age at FGR onset and at delivery (Table 380 
2). Maternal ethnicity differed  between study groups, with the late-onset FGR group containing the 381 
largest proportion of Asian, black or mixed ethnicity subjects and the AGA group containing the smallest 382 
proportion of subjects of these ethnicities. Women with FGR fetuses were more likely than women with 383 
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hypertension, pre-eclampsia or HELLP syndrome.  Hypertensive disorder of pregnancy was highest in the 385 
preterm, early-onset FGR group. As expected, women in the preterm, early-onset FGR group delivered 386 
earlier than the other three groups, by ~10 weeks on average. Placental weight differed significantly 387 
between AGA and FGR groups but was not recorded for all subjects (Table 2).  Both birth weight and 388 
placental SLC38A2 expression were lower in late-onset FGR pregnancies than AGA pregnancies, by 38% 389 
and 60%, respectively (Fig. 5). Contrastingly, early-onset FGR pregnancies delivered at term had 390 
birthweights that were 33% lighter than AGA control birthweights, but their placental SLC38A2 expression 391 
levels did not differ significantly, and tended to be higher than control values (Fig. 5B). Placental SLC38A2 392 
expression also tended to be higher in term-delivered early-onset FGR pregnancies compared to their 393 
preterm-delivered counterparts, which had even lower birth weights (Fig. 5A, B). 394 
Within subjects delivering at term, placental SLC38A2 expression correlated with placental weight 395 
(P=0.005, R=0.664, n=16) and gestational age at delivery (P=0.008, R=0.501, n=27) but did not correlate 396 
with any of the other continuous independent variables (Table S2). When FGR status and potential 397 
confounding variables (gestational age, maternal ethnicity and hypertensive disorder) were entered into 398 
a multiple linear regression model to predict placental SLC38A2 expression at term, the overall effect of 399 
FGR status remained significant (main effect: P<0.001; regression model: P<0.001, R2=0.769, degrees of 400 
freedom=21). Regression coefficients for the adjusted effect of each type of FGR, compared to AGA, 401 
further indicated decreased SLC38A2 expression in late-onset FGR (P=0.058, β=-0.389) and increased 402 
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This study shows, for the first time, that placenta-specific knockdown of the System A amino acid 405 
transporter Slc38a2/SNAT2 causes fetal growth restriction in mice, consistent with our original 406 
hypothesis. Lower fetal weight in Slc38a2KD transduced conceptuses was accompanied by diminished 407 
fetal viability, lower placental weight, lower maternal-fetal MeAIB clearance and lower fetal islet GSIS 408 
near term, compared to control transduced conceptuses. The study also provides the first demonstration 409 
that human placental SLC38A2 expression is reduced at term in FGR pregnancies compared to AGA 410 
pregnancies, specifically when FGR is late in onset, occurring after 32 weeks of gestation, but not when it 411 
is diagnosed before. Our study therefore proves that normal trophoblast Slc38a2/SNAT2 expression and 412 
function are necessary for normal fetal growth and supports the concept that impaired placental System 413 
A amino acid transport mechanistically contributes to human late-onset FGR.  414 
The 11% reduction in fetal weight with placenta-specific Slc38a2 knockdown was similar in magnitude to 415 
that observed in mouse embryos with global Slc38a2 deletion (32) and in rat embryos following inhibition 416 
of System A amino acid transport using unlabeled MeAIB infusion (31). These findings are all consistent 417 
with the physiological role of SNAT2 as an active transporter of amino acids across the rodent placenta, 418 
where it is abundantly expressed in the labyrinthine trophoblast plasma membrane and correlates with 419 
fetal size (28, 63, 64). Fetal growth restriction in our study was attributable to a deficiency of trophoblast 420 
membrane SNAT2 and overall functional reduction in System A-mediated amino acid delivery to the 421 
umbilical circulation, because transplacental MeAIB clearance was 23% lower in Slc38a2KD than SCR 422 
conceptuses. However, Slc38a2 silencing also caused placental growth restriction, which preceded fetal 423 
growth restriction, alongside diminished placental System A amino acid uptake per unit mass of tissue. 424 
The fact that transplacental MeAIB clearance per gram of placenta was not changed therefore suggests 425 
that the fetal effect of Slc38a2 knockdown was partly mediated by smaller placental size, and 426 
consequently reduced exchange surface area, as well as lower SNAT2 transporter density in the 427 
trophoblast plasma membrane. Lower placental weight in Slc38a2KD conceptuses was not related to 428 
inhibition of the nutrient-sensing amino acid response and mechanistic target of rapamycin signaling 429 
pathways, which regulate trophoblast growth in vitro (65, 66). Instead, SNAT2 deficiency in the 430 
trophoblast plasma membrane probably directly reduced intracellular amino acid availability for cellular 431 
accretion or proliferation. Indeed, mouse placentas genetically lacking Slc38a4/SNAT4 exhibit mid-432 
gestation hypoplasia, with reduced expression of cell-cycle related genes and lower numbers of 433 






S20210575/919305/cs-2021-0575.pdf by guest on 19 August 2021
C
linical Science. This is an Accepted M
anuscript. You are encouraged to use the Version of R
ecord that, w
hen published, w
ill replace this version. The m




global genetic deletion of Slc38a2 does not alter placental weight at term (32). This may suggest that 435 
compensatory processes maintain placental size during differentiation of the trophectoderm when 436 
Slc38a2 is deleted by zygotic CRISPR-Cas9 injection, albeit the number of Slc38a2-deficient placentas 437 
analysed in the previous study was very small.  438 
Near term fetal viability rate was reduced by 33% in Slc38a2KD embryos, whereas implantation rates were 439 
similar to controls, in line with the effect of global Slc38a2 deletion (32, 33). Therefore, a greater 440 
proportion of Slc38a2KD embryos died after implantation but before term. This finding reflects the 441 
increased incidence of stillbirth and perinatal death seen in FGR human fetuses (67-69) and supports the 442 
importance of placental SNAT2 for normal fetal development. It indicates that SNAT2 may be involved in 443 
post-implantation development, earlier in gestation. Certainly, SNAT2 is abundantly expressed in the peri-444 
implantation mouse embryo and plays a role in embryonic stem cell differentiation, although its role in 445 
extraembryonic cells in early gestation is not well established (70, 71).  446 
The effects of placenta-specific Slc38a2 knockdown on fetal growth were generally milder than those of 447 
glucocorticoid excess, hypoxia, protein restriction or nitric oxide deficiency in pregnant rodents, which are 448 
similarly associated with reduced System A amino acid transport (28, 34-36, 38). This is probably explained 449 
by the tendency for these perturbations to reduce fetal delivery of other nutrients and oxygen by altering 450 
uteroplacental blood flow. Additionally, some of these insults are associated with placental 451 
downregulation of the other System A amino acid transporters, Slc38a1/SNAT1 or Slc38a4/SNAT4 (29, 34, 452 
38), which may have additive effects on net transplacental amino acid transport. Placental Slc38a1 and 453 
Slc38a4 expression was maintained at normal levels in our study, by design. The relative importance of 454 
Slc38a2/SNAT2 compared to the other two placental SNAT transporter isoforms is still being established 455 
and appears to vary with species. Global deletion of either Slc38a1, Slc38a2 or Slc38a4 reduces fetal 456 
growth in mice (32), whilst studies in isolated microvillous membrane indicate that SNAT1 and SNAT2 457 
mainly mediate neutral amino acid uptake in rat syncytiotrophoblast (72). In humans, in vitro experiments 458 
demonstrate that SNAT1, SNAT2 and SNAT4 all contribute to trophoblast System A-mediated amino acid 459 
uptake, depending on gestational age (23, 24, 72, 73), but placental SNAT2 abundance is most closely 460 
related to term fetal growth (22, 26). The present study shows that exclusively reducing placental Slc38a2 461 
expression is sufficient to impair maternal-fetal System A amino acid transport and fetal growth. Notably, 462 
fetal growth restriction occurred even though placental Slc38a2 silencing did not affect net placental 463 
uptake or transplacental transport of the essential amino acid, leucine. This finding was unexpected, given 464 
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depend on the intracellular concentration of non-essential amino acids accumulated by System A (20). 466 
This observation may be partly explained by computational modelling data suggesting that placental L-467 
type amino acid transporters are not obligate exchangers but can also act as facilitated transporters (74). 468 
Although reduced fetal weight in our study is partly explained by low amino acid availability for tissue 469 
accretion, it may also be indirectly attributed to fetal hyperinsulinaemia, due to impaired pancreatic islet 470 
function. Our finding of reduced GSIS in Slc38a2KD fetal pancreatic islets reflects that in growth restricted 471 
human and sheep fetuses with reduced umbilical amino acid concentration, β-cell mass and pancreatic 472 
expression of the transcription factor Pdx1 (75-79). Pdx1 is a key differentiation initiator in pancreatic 473 
progenitor cells and activator of β-cell specific genes, and is regulated by amino acids, including the System 474 
A substrate, glutamine (80). Therefore, at a cellular and molecular level, reduced GSIS in pancreatic islets 475 
from Slc38a2KD fetuses is most likely due to deficient β cell development caused by amino acid 476 
deprivation and Pdx1 downregulation.  477 
The physiological effects of placental Slc38a2 silencing were not in proportion to the degree of knockdown 478 
of mRNA expression, which was decreased by more than 50%. This reflects the limitation of using RNAi 479 
methodology to study placental membrane-bound transporter function, which is also governed by the 480 
rates of translation and, particularly, trafficking of the transporter proteins to the plasma membrane (27). 481 
Furthermore, lower viability in Slc38a2KD fetuses may have contributed to an underestimation of the 482 
effect on nutrient transport and fetal growth, because fetal weight in rodents is inversely related to the 483 
number of fetuses in each horn (81). Although the experimental design controlled for effects of overall 484 
litter size, by transferring control and Slc38a32KD embryos to contralateral horns of each recipient uterus, 485 
the relative difference in fetal weight and amino acid transport would most likely have been larger if we 486 
controlled the number of viable fetuses per horn. The full magnitude of the effect of placenta-specific 487 
Slc38a2 silencing may also have been masked if those embryos with greatest functional knockdown of 488 
SNAT2 were resorbed prior to the E18.5 analyses. Nevertheless, our study demonstrates that lentiviral 489 
shRNA-mediated gene silencing is effective as a tool to study placental nutrient transporter function in 490 
mice. 491 
This is the first study to determine human placental SLC38A2 expression in well-defined early- and late-492 
onset FGR subjects delivering at term. The reduction in SLC38A2 gene expression in placentas with late-493 
onset FGR was consistent with, but greater in magnitude than, that reported in another cohort, which had 494 
a mean gestational age of ~33 weeks and most likely represented a mixed population of early- and late-495 
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deficiency in late-onset FGR. By contrast, the lack of reduction in SLC38A2 expression in early-onset FGR 497 
placentas was unexpected. It may suggest that amino acid transport is causatively less important than 498 
factors such as impaired spiral artery remodelling and uteroplacental blood flow in early-onset FGR (44). 499 
Alternatively, early-onset FGR may be underpinned by reduced post-translational trafficking of SNAT2 to 500 
the trophoblast plasma membrane, due to suppressed mechanistic target of rapamycin signalling (22), 501 
rather than decreased SLC38A2 transcription per se. We were unable to measure membrane localized 502 
transporter abundance or System A activity using the small amounts of human placental material 503 
collected in this study. The analyses of human placentas were also limited by the small number of patients 504 
with early onset FGR that reached term for delivery; the lack of preterm AGA control placentas; and our 505 
inability to control for possible effects of maternal ethnicity or hypertensive disorders, which differed 506 
between AGA and FGR subjects. Nevertheless, the data provide compelling evidence that early- and late-507 
onset FGR are underpinned by different mechanisms, with reduced placental amino acid transport critical 508 
in the latter. 509 
Overall, this study is the first demonstration of a cause-and-effect relationship between placental 510 
Slc38a2/SNAT2 expression and fetal growth. Prior to this study, there was no definitive evidence that 511 
SNAT2 deficiency mechanistically contributes to FGR. Given that System A amino acid transporter activity 512 
is compromised more severely in human FGR placentas (>70% (22)) than in this study (23%), the results 513 
strongly indicate that diminished fetal amino acid supply is an underlying cause. Currently, there is no 514 
specific treatment of FGR in the clinic.  Our findings suggest that interventions that augment placental 515 
System A amino acid transport capacity may improve fetal growth and outcomes in severe fetal growth 516 
restriction.  These interventions may be most effective in women diagnosed with late-onset FGR, which 517 
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FIGURE LEGENDS 755 
Fig. 1 Placenta-specific Slc38a2 knockdown reduces placental and fetal weights at E18.5. (A) Gene 756 
expression of Slc38a1, Slc38a2 and Slc38a4 in placentas of SCR and Slc38a2KD conceptuses, n=6 litters (28 757 
SCR placentas, 13 Slc38a2KD placentas). (B) Slc38a2 expression in selected fetal tissues from SCR and 758 
Slc38a2 conceptuses, pooled from n=6 litters (27 SCR fetuses, 15 Slc38a2KD fetuses. (C) Fetal weight and 759 
(D) placental weight in SCR and Slc38a2KD conceptuses from n=29 litters (130 SCR conceptuses and 99 760 
Slc38a2KD conceptuses). Points represent litter means. (A-D) Litter mean values for SCR and Slc38a2 761 
compared by paired Student’s t-test. P values for statistically significant differences (P<0.05) given in 762 
figure. Mean  ± SEM. (E) Correlation of fetal weight with placental Slc38a2 expression for individual SCR 763 
(n=28) and Slc38a2KD (n=13) conceptuses. Points represent individual conceptuses. Pearson correlation 764 
coefficient (R) and P value given in figure. Linear regression line with 95% confidence intervals shown. (F) 765 
Frequency distribution of individual fetal weights in SCR (n=130) and Slc38a2KD conceptuses (n=99). 766 
Gaussian curves fitted by least-squares non-linear regression and compared by extra sum-of-squares F-767 
test (P value given in figure). Best-fit values for curves: SCR amplitude 18.7 ± 1.2 %, mean 1034 ± 7 mg, SD 768 
101 ± 7 mg; Slc38a2KD amplitude 17.2 ± 1.3 %, mean 952 ± 10 mg, SD 113 ± 10 mg. Dotted vertical line 769 
indicates 10th percentile of SCR fetal weights. 770 
Fig. 2 Placenta-specific Slc38a2 knockdown reduces trophoblast plasma membrane SNAT2 abundance 771 
and placental System A amino acid transport. (A) SNAT2 protein abundance in isolated trophoblast 772 
plasma membranes from pooled SCR and Slc38a2KD placentas, determined by Western blot. 773 
Representative blot includes human placental microvillous membrane (MVM) sample, as positive control. 774 
(B-E) Placental uptake and transplacental transport of 14C-methylaminoisobutyric acid in SCR (n=13 litters, 775 
representing 46 conceptuses) and Slc38a2KD conceptuses (n=13 litters, representing 58 conceptuses), 776 
expressed as absolute values (B, C) and per gram of placenta (D, E). Litter mean values for SCR and 777 
Slc38a2KD conceptuses compared by paired t-test. P values for significant differences (P<0.05) given in 778 
figure. Mean + SEM (F) Correlation of fetal weight with placental 14C-methylaminoisobutyric acid uptake 779 
for SCR (n=46) and Slc38a2KD (n=58) conceptuses. Points represent individual conceptuses. Pearson 780 
correlation coefficient (R) and P value given in figure. Linear regression line with 95% confidence intervals 781 
shown.  782 
Fig. 3 Placental System L amino acid transport in SCR and Slc38a2KD conceptuses. (A, B) Placental uptake 783 
and (C, D) transplacental transport of 3H-leucine, expressed as absolute values (A, C) or per gram placenta 784 
(B, D). n=9 litters (33 SCR conceptuses, 29 Slc38a2KD conceptuses. Litter mean values for SCR and 785 
Slc38a2KD conceptuses compared by paired Student’s t –test. P values for significant differences (P<0.05) 786 
given in figure. Mean + SEM 787 
Fig. 4 Placenta-specific Slc38a2 knockdown decreases fetal islet glucose-stimulated insulin secretion.  788 
GSIS from mouse fetal islet cells. Pancreatic fetal islets were isolated, and GSIS determined in response to 789 
stimulation with (A) 2.8 mM and (B) 10.0 mM glucose for 60. (C) Fetal blood glucose was measured in 790 
trunk blood. n=7 litters/group. GSIS and blood glucose for SCR and Slc38a2KD conceptuses compared by 791 
paired Student’s t –test. P values for significant differences (P<0.05) given in the figure. Mean + SEM.  792 
Fig. 5 Human placental SLC38A2 expression is decreased in late- but not early-onset FGR. (A) Birth 793 
weights and (B) placental relative SLC38A2 expression levels in AGA and FGR neonates, delivered at term 794 
(≥37 weeks gestation) or preterm (<37 weeks gestation, early-onset FGR only). Birth weights were 795 






S20210575/919305/cs-2021-0575.pdf by guest on 19 August 2021
C
linical Science. This is an Accepted M
anuscript. You are encouraged to use the Version of R
ecord that, w
hen published, w
ill replace this version. The m




using Sidak’s multiple comparisons test. SLC38A2 expression was statistically compared between groups 797 
using Kruskal-Wallis test (P<0.001) with planned post-hoc comparisons using Dunn’s multiple comparisons 798 
test. P values for post-hoc tests given in figure. AGA n=15, late-onset FGR n=8, term early-onset FGR n=4, 799 
preterm early-onset FGR n=17. Boxes are median with IQR, whiskers are range. 800 
 801 
 802 
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Table 1 Implantation and viability rates for SCR and Slc38a2KD transduced embryos at E18.5 
 
 SCR Scl38a2KD P value 
Total embryos transferred (n) 550 538  
Implanted (n) 195 165  
% 35% 31% 0.094a 
Viable fetus at E18.5 178 113  
% 32% 21% <0.001a 
Number of fetuses per uterine horn 
(median, min-max) 
4 (0-9) 2 (0-12) <0.001b 
 
Embryos were transferred to 58 recipient dams, of which 47 were pregnant, with any number of 
implantations, and 11 were non-pregnant at E18.5. SCR and Slc38a2 were compared by aFisher’s exact 
test or bMann-Whitney U-test. 
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Table 2 Demographic characteristics of human AGA and FGR study participants. 
 
 Term delivery Preterm 
delivery 
P value 




























Ethnicity (number Asian, 











of pregnancy (number 


















































      
 
Continuous variables are given as median (interquartile range) and compared by one-way ANOVAa with 
Sidak’s multiple comparison post-hoc, or by Kruskal-Wallis testb with Dunn’s multiple comparison post-
hoc; *significantly different from AGA, †significantly different from early-onset FGR delivered at term. 
Categorical variables are given as number (% of n) and compared by chi-squared testc. dPlacental weights 
were collected for a subset of study participants: AGA n=9, late onset FGR n=6, term early-onset FGR n=1, 
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Fig. 1 Placenta-specific Slc38a2 knockdown reduces placental and fetal weights at E18.5. (A) Gene
expression of Slc38a1, Slc38a2 and Slc38a4 in placentas of SCR and Slc38a2KD conceptuses, n=6 litters (28
SCR placentas, 13 Slc38a2KD placentas). (B) Slc38a2 expression in selected fetal tissues from SCR and
Slc38a2 conceptuses, pooled from n=6 litters (27 SCR fetuses, 15 Slc38a2KD fetuses. (C) Fetal weight and
(D) placental weight in SCR and Slc38a2KD conceptuses from n=29 litters (130 SCR conceptuses and 99
Slc38a2KD conceptuses). Points represent litter means. (A-D) Litter mean values for SCR and Slc38a2
compared by paired Student’s t-test. P values for statistically significant differences (P<0.05) given in figure.
Mean ± SEM. (E) Correlation of fetal weight with placental Slc38a2 expression for individual SCR (n=28) and
Slc38a2KD (n=13) conceptuses. Points represent individual conceptuses. Pearson correlation coefficient (R)
and P value given in figure. Linear regression line with 95% confidence intervals shown. (F) Frequency
distribution of individual fetal weights in SCR (n=130) and Slc38a2KD conceptuses (n=99). Gaussian curves
fitted by least-squares non-linear regression and compared by extra sum-of-squares F-test (P value given in
figure). Best-fit values for curves: SCR amplitude 18.7 ± 1.2 %, mean 1034 ± 7 mg, SD 101 ± 7 mg; Slc38a2KD
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Fig. 2 Placenta-specific Slc38a2 knockdown reduces trophoblast plasma membrane SNAT2 abundance
and placental System A amino acid transport. (A) SNAT2 protein abundance in isolated trophoblast plasma
membranes from pooled SCR and Slc38a2KD placentas, determined by Western blot. (B-E) Placental uptake
and transplacental transport of 14C-methylaminoisobutyric acid in SCR (n=13 litters, representing 46
conceptuses) and Slc38a2KD conceptuses (n=13 litters, representing 58 conceptuses), expressed as
absolute values (B, C) and per gram of placenta (D, E). Litter mean values for SCR and Slc38a2KD
conceptuses compared by paired t-test. P values for significant differences (P<0.05) given in figure. Mean +
SEM (F) Correlation of fetal weight with placental 14C-methylaminoisobutyric acid uptake for SCR (n=46) and
Slc38a2KD (n=58) conceptuses. Points represent individual conceptuses. Pearson correlation coefficient (R)
and P value given in figure. Linear regression line with 95% confidence intervals shown.
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Fig. 3 Placental System L amino acid transport in SCR and Slc38a2KD conceptuses. (A, B) Placental uptake
and (C, D) transplacental transport of 3H-leucine, expressed as absolute values (A, C) or per gram placenta
(B, D). n=9 litters (33 SCR conceptuses, 29 Slc38a2KD conceptuses. Litter mean values for SCR and
Slc38a2KD conceptuses compared by paired Student’s t –test. P values for significant differences (P<0.05)
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Fig. 4 Placenta-specific Slc38a2 knockdown decreases fetal islet glucose-stimulated insulin
secretion. Pancreatic fetal islets were isolated, and GSIS determined in response to stimulation with
(A) 2.8 mM and (B) 10.0 mM glucose for 60. (C) Fetal blood glucose was measured in trunk blood. (D)
Pdx1 abundance was determined in islets by western blot. n=6-7 litters/group. GSIS and blood
glucose for SCR and Slc38a2KD conceptuses compared by paired Student’s t –test. P values for
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Fig. 5 Human placental SLC38A2 expression is decreased in late- but not early-onset FGR.
(A) Birth weights and (B) placental relative SLC38A2 expression levels in AGA and FGR
neonates, delivered at term (≥37 weeks gestation) or preterm (<37 weeks gestation). Birth
weights were statistically compared between groups by one-way ANOVA (P<0.001) with
planned post-hoc comparisons using Sidak’s multiple comparisons test. SLC38A2 expression
was statistically compared between groups using Kruskal-Wallis test (P<0.001) with planned
post-hoc comparisons using Dunn’s multiple comparisons test. P values for post-hoc tests
given in figure. AGA n=15, late-onset FGR n=8, term early-onset FGR n=4, preterm early-
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